DBV Technologies S.A. (DBVT) Stock
DBVT has an Alpha Score of 38 out of 100 (weak), computed on Nov 5, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported DBVT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Duquesne Family Office's at $6.29M.
What is DBVT's Alpha Score?
How it works →Alpha Score of 38 reflects weak overall profile with moderate momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own DBVT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Duquesne Family Office Stanley Druckenmiller | 383K | $6.29M | n/a |
| Millennium Management Israel Englander | 268K | $4.39M | -16% |
| Citadel Ken Griffin | 23K | $373.6K | NEW |
| Point72 Steve Cohen | 12K | $199.2K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are DBV Technologies S.A. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Jul 29, 26 | Mohideen Pharis | Chief Medical Officer | SELL | 464 | $1K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are DBVT's key statistics?
Key statistics as of Nov 5, 2026
How does DBVT's valuation compare with the Healthcare sector?
| Metric | DBVT | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -2611.00% | 3.60% | 175 |
| Return on equity | -115.44% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
DBVT price chart
Powered by TradingViewWhat does DBV Technologies S.A. do?
DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Bagneux, France, specializing in immunotherapy treatments for food allergies. The company is known for developing the Viaskin patch, a proprietary transdermal technology designed to administer allergens to intact skin while preventing transfer to the bloodstream. DBV Technologies' primary focus is addressing peanut allergies and cow's milk allergies in pediatric populations, conditions for which limited effective treatment options currently exist. The company's lead candidates include Viaskin Peanut, which aims to help patients tolerate peanut exposure and reduce the risk of severe allergic reactions from accidental exposure, and Viaskin Milk for milk allergy treatment. Viaskin Peanut has received Fast Track designation from the US Food and Drug Administration, reflecting its potential significance in addressing unmet medical needs. Additionally, DBV Technologies developed the E-patch, a standardized diagnostic tool for identifying allergies in children. Founded in 2002, the company operates as a publicly traded biopharmaceutical firm focused on transforming treatment approaches within the immunotherapy field.